Physician profile
Anna Horne
NPI 1942921135
$1,850.74
in general payments reported to CMS, 2019-2025
22 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $181 · 2023: $579 · 2024: $824 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,669.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $462.39 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $277.30 | 2023-2025 | Airsupra, Farxiga |
| Abbvie INC. | $189.52 | 2023-2025 | |
| Glaxosmithkline, LLC. | $127.72 | 2023-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $122.35 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $113.89 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $93.88 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $65.33 | 2024-2025 | Spravato |
| Axsome Therapeutics, INC. | $52.02 | 2024 | Auvelity |
| Phathom Pharmaceuticals, INC. | $51.84 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $42.00 | 2022-2023 | Rexulti |
| Vbi Vaccine (Delaware) INC. | $40.91 | 2022 | |
| Novartis Pharmaceuticals Corporation | $36.68 | 2023 | |
| Amgen INC. | $30.76 | 2023-2024 | Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.21 | 2024 | Caplyta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $22.23 | 2023 | Prolate, Nalocet |
| Ironshore Pharmaceuticals INC. | $18.46 | 2023 | Jornay Pm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.89 | 2023 | Trulance, Xifaxan |
| Corium, LLC | $15.34 | 2023 | Azstarys |
| Lundbeck LLC | $15.20 | 2024 | Rexulti |
| Exact Sciences Corporation | $15.10 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $14.72 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Horne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.